US2011027281A1PendingUtilityA1

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor

58
Assignee: ABLYNX NVPriority: Nov 8, 2002Filed: Oct 15, 2010Published: Feb 3, 2011
Est. expiryNov 8, 2022(expired)· nominal 20-yr term from priority
Inventors:Karen SilenceMarc Jozef LauwereysHans De Haard
A61P 31/00A61P 37/06A61P 31/04A61P 35/00A61K 2039/505C07K 2317/569C07K 2317/31C07K 2317/76C07K 2317/24C07K 16/18C07K 2317/565C07K 16/2863A61P 19/02C07K 16/40C07K 16/4291C07K 2317/92C07K 16/2875C07K 2317/22C07K 2319/00C07K 16/241C07K 2317/626C07K 16/249C07K 2317/567C07K 16/36C07K 2317/34
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.

Claims

exact text as granted — not AI-modified
1 . A composition comprising a first and a second anti-TNF-alpha antibody single variable domain and an anti-serum albumin antibody single variable domain, wherein said first and second anti-TNF-alpha antibody single variable domains have the same TNF-alpha epitope binding specificity. 
     
     
         2 . The composition of  claim 1 , wherein said first and second anti-TNF-alpha antibody single variable domains are identical. 
     
     
         3 . The composition of  claim 1 , wherein the anti-TNF-alpha antibody single variable domains have a monomer surface plasmon resonance K D  of about 300 nM to about 5 pM. 
     
     
         4 . The composition of  claim 3 , wherein said monomer surface plasmon resonance K D  is about 50 nM to about 20 pM. 
     
     
         5 . The composition of  claim 4 , wherein said monomer surface plasmon resonance K D  is about 1 nM to about 100 pM. 
     
     
         6 . The composition of  claim 1 , wherein said composition has at beta half-life of at least 24 hours. 
     
     
         7 . The composition of  claim 1 , wherein said composition has at beta half-life of 12 hours to 48 hours. 
     
     
         8 . The composition of  claim 1 , wherein said composition has at beta half-life of 12 hours to 26 hours. 
     
     
         9 . A composition comprising a first and a second anti-TNF-alpha antibody single variable domain and an anti-serum albumin antibody single variable domain, wherein said composition has at beta half-life of at least 12 hours. 
     
     
         10 . The composition of  claim 9 , wherein said composition has at beta half-life of at least 24 hours. 
     
     
         11 . The composition of  claim 9 , wherein said composition has at beta half-life of 12 hours to 48 hours. 
     
     
         12 . The composition of  claim 9 , wherein said composition has at beta half-life of 12 hours to 26 hours. 
     
     
         13 . The composition of  claim 9 , comprising one anti-serum albumin antibody single variable domain. 
     
     
         14 . The composition of  claim 9 , wherein said first and second anti-TNF-alpha antibody single variable domains and said anti-serum albumin antibody single variable domains form a fusion polypeptide. 
     
     
         15 . The composition of  claim 9 , wherein said first and second anti-TNF-alpha antibody single variable domains compete with TAR1-5-19 to bind TNF-alpha in an ELISA assay. 
     
     
         16 . The composition of  claim 9 , wherein the anti-TNF-alpha antibody single variable domains have the same TNF-alpha epitope binding specificity. 
     
     
         17 . The composition of  claim 9 , wherein said first and second anti-TNF-alpha antibody single variable domains are identical. 
     
     
         18 . The composition of  claim 9 , wherein the anti-TNF-alpha antibody single variable domains have a monomer surface plasmon resonance K D  of about 300 nM to about 5 pM. 
     
     
         19 . The composition of  claim 18 , wherein said monomer surface plasmon resonance K D  is about 50 nM to about 20 pM. 
     
     
         20 . The composition of  claim 19 , wherein said monomer surface plasmon resonance K D  is about 1 nM to about 100 pM. 
     
     
         21 . The composition of  claim 9 , wherein each antibody single variable domain is linked to a polypeptide linker. 
     
     
         22 . The composition of  claim 9 , wherein said first and second anti-TNF-alpha antibody single variable domain and said anti-serum albumin antibody single variable domain are linked. 
     
     
         23 . A kit comprising the composition of  claim 9 , and instructions for its use. 
     
     
         24 . A pharmaceutical composition comprising the composition of  claim 9  and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2011027281A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.